Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

One-Time gene shot aims to halt rare muscle disease

NCT ID NCT06246513

First seen Mar 27, 2026 · Last updated May 24, 2026 · Updated 13 times

Summary

This study tests a single dose of SRP-9003 gene therapy in 17 people with limb-girdle muscular dystrophy 2E/R4, a rare genetic muscle-weakening disease. The goal is to see if the therapy can restore a missing protein in muscle cells and improve function. Both walkers and non-walkers are included, and the study is currently active but not recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIMB-GIRDLE MUSCULAR DYSTROPHY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Children's Hospital of The King's Daughter

    Norfolk, Virginia, 23507, United States

  • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

    Milan, 20122, Italy

  • Hospital Sant Joan de Deu

    Barcelona, 8950, Spain

  • NMRC Gent (UZ Gent)

    Ghent, 9000, Belgium

  • Nationwide Childrens Hospital

    Columbus, Ohio, 43205, United States

  • Newcastle University

    Newcastle upon Tyne, NE1 3BZ, United Kingdom

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Universitatsklinikum Essen; Kinderklinik I, Sozialpadiatrisches Zentrum

    Essen, North Rhine-Westphalia, 45147, Germany

  • University Hospital Leuven (UZ Leuven)

    Leuven, Vlaams Brabant, 3000, Belgium

  • University of California, San Diego-Altman Clinical and Translational Research Institute

    La Jolla, California, 92037, United States

Conditions

Explore the condition pages connected to this study.